Grunenthal GmbH
http://www.grunenthal.com
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Grunenthal GmbH
Breaking The Pain Market’s Addiction To Opioids
The recent success of Vertex in acute pain merely highlights the agonizingly slow process elsewhere, particularly in chronic pain indications.
US FDA’s Breakthrough Designation Pace Slows, But Topics Broaden
The 19 breakthrough therapy designations awarded so far this year run the gamut from areas that traditionally have not fared well with BTDs, like cardiovascular and respiratory disease, alongside the traditional cancer and orphan disease tentpoles.
Finance Watch: Biopharma Stocks Attempt An April Rebound
Public Company Edition: With the XBI up more than 9% in April, a few follow-on offerings –$23m to support Gamida Cell’s small product launch and $500m to fund Vaxcyte’s large clinical trial program – have made it to market. Also, China’s CytoMed launched the sixth biopharma IPO in the US this year.
Kyowa Kirin To Offload Selected Mature Portfolio To Grünenthal
The Japanese and German firms agree to establish a joint company to handle 13 mature brands from Kyowa Kirin's portfolio, mainly focused on pain management and including Abstral and PecFent. Grünenthal will own 51% and plans to fully buy out the operation in early 2026.
Company Information
- Industry
- Medical Devices
- Pharmaceuticals
- Other Names / Subsidiaries
-
- Adhesys Medical GmbH
- Adhesys Medical Inc.
- Averitas Pharma, Inc.
- Grunenthal GmbH
- Gruenenthal GmbH
- Grunental GmbH
- Inversiones Gruchi S.A.
- Inversiones Gruchi Limitada
- Laboratorios Andrómaco S.A.
- Laboratoires Grunenthal SAS
- Mestex AG
- Thar Pharmaceuticals, Inc.
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice